PULSE BIOSCIENCES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PLSE in the last 30 days.
See all $PLSE insider activity →Oppenheimer raised its price target for Pulse Biosciences (PLSE) to $60 from $35, citing competitor challenges. The stock trades at $52.45 with a $3.74B market cap. Analysts highlight a pivotal trial in 2027 and recent equity agreements. Multiple analysts initiated coverage with buy ratings and price targets ranging from $58 to $73.
PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California , October 7, 2026 — Puls
Pulse Biosciences (PLSE) completed enrollment in its NANOPULSE-AF Study for treating atrial fibrillation, hitting its 164-patient target three months early. The study evaluates the safety and effectiveness of its nPulse Cardiac Catheter System. Primary endpoints will be assessed at six and 12 months post-ablation. The company plans to share updates and present data at future conferences.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning PLSE (PULSE BIOSCIENCES, INC.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.
Recent PLSE coverage spans corporate actions, financial news and technology.
Analyst upgrade and equity distribution agreement suggest near‑term upside.
Enrollment success signals strong trial momentum, likely supporting near‑term share price appreciation.
Enrollment completion is a positive catalyst that may improve market sentiment toward PLSE as the trial progresses toward data readout.
Analyst upgrade and fresh financing could lift the stock.
Potential cash infusion of up to $85M with dilution risk; no immediate sales obligation.
AlphAI scores every news story that mentions PLSE with an AI model for sentiment and relevance, and aggregates insider trades from PULSE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer raised its price target for Pulse Biosciences (PLSE) to $60 from $35, citing competitor challenges. The stock trades at $52.45 with a $3.74B market cap. Analysts highlight a pivotal trial in 2027 and recent equity agreements. Multiple analysts initiated coverage with buy ratings and price targets ranging from $58 to $73.
2 min readPULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California , October 7, 2026 — Puls
2 min readPulse Biosciences (PLSE) completed enrollment in its NANOPULSE-AF Study for treating atrial fibrillation, hitting its 164-patient target three months early. The study evaluates the safety and effectiveness of its nPulse Cardiac Catheter System. Primary endpoints will be assessed at six and 12 months post-ablation. The company plans to share updates and present data at future conferences.
1 min readCanaccord raised its price target on Pulse Biosciences (PLSE) to $58 from $43, maintaining a Buy rating. The stock has surged 87.5% since Canaccord initiated coverage and 268% year-to-date, with a $3.6B market cap. The firm cited the company's nanosecond pulse field ablation platform and clinical progress. Pulse also announced an equity distribution agreement with Mizuho Securities for up to $85M in common stock sales.
2 min readPULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may o
1 min readPULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse ™ Vybrance ™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed
1 min readWealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.
2 min readPulse Biosciences (PLSE) stock rose 10% after analyst Keith Hinton initiated coverage with a buy rating and $73 price target, citing potential in atrial fibrillation ablation. Hinton highlights the company's proprietary NPS technology and strong cash position, with clinical trials underway. Success could lead to a buyout by mid-2027, according to the analyst.
2 min readOpus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.
3 min readModular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
3 min read
